Adaptive Biotechnologies is trading 4.3% lower at $24.49, with no clear company-specific announcement explaining the October 16, 2026 decline.
- A reported COO share sale was made under a pre-arranged Rule 10b5-1 plan; recent analyst price-target increases are not an obvious negative catalyst.
- Hotter-than-expected inflation revived interest-rate concerns and cautious sentiment.
- Available sector context points to biotech strength, so the decline cannot confidently be attributed to a broad sector selloff.